LINC00486: A Long Intergenic Non-Protein Coding RNA and Its Potential as a Drug Target

Target Name: LINC00486

NCBI ID: G285045

LINC00486

Other Name(s): Long intergenic non-protein coding RNA 486, transcript variant 4 | long intergenic non-protein coding RNA 486 | Long intergenic non-protein coding RNA 486, transcript variant 1

LINC00486: A Long Intergenic Non-Protein Coding RNA and Its Potential as a Drug Target

Introduction

LINC00486 is a long intergenic non-protein coding RNA (lncRNA) located on chromosome 16 at position 111.2 kb. It is characterized by a unique structure, which consists of a single exon and a variable-length non-coding region that covers several exons ( 1-3) on the 5' and 3' ends.

LINC00486 is a non-coding RNA that has been shown to play a critical role in various cellular processes, including cell adhesion, migration, and the regulation of gene expression. The function of LINC00486 is not well understood, but its unique structure and expression patterns have led to its potential as a drug target.

Molecular Characterization

The full-length RNA sequence of LINC00486 is 292 nucleotides long and has a 29.4% identity to the human reference transcript (HGNC). It has a unique 5' and 3' end, which consists of a 29-nt long untranslated region (UTR ) and a 6-nt coding region ( exon 1) at the 5' end and a 7-nt UTR at the 3' end ( figure 1).

The 5' end of LINC00486 contains a 29-nt UTR that is highly conserved across various species, including humans. The 3' end of the RNA contains a 6-nt UTR that is also conserved across species but shows some diversity at the nucleotide level.

Expression and Localization

LINC00486 is expressed in various tissues and cell types, including brain, pancreas, and heart. It is highly expressed in the brain, with a 7-fold increase in expression compared to the pancreas or heart. It is also expressed in other tissues, including muscle and skin.

LINC00486 is primarily localized to the cytoplasm of the cells, with a low expression in the nucleus. It is also found in the endoplasmic reticulum (ER) and the nuclear p-time, but at much lower levels than in the cytoplasm.

Function and Potential as a Drug Target

The unique structure and expression patterns of LINC00486 have led to its potential as a drug target. Several studies have suggested that LINC00486 may play a role in various cellular processes, including cell adhesion, migration, and the regulation of gene expression.

One potential mechanism by which LINC00486 may function as a drug target is through its role in cell adhesion. LINC00486 has been shown to be involved in the regulation of tight junction formation, a critical process that ensures the integrity of cell membranes.

Another potential mechanism by which LINC00486 may function as a drug target is through its role in cell migration. LINC00486 has been shown to be involved in the regulation of cell migration, including the migration of cancer cells.

In addition, LINC00486 may also be involved in the regulation of gene expression. It has been shown to interact with various transcription factors, including NF-kappa-B and SMAD3.

Conclusion

LINC00486 is a long intergenic non-protein coding RNA that has unique structure and expression patterns. Its potential as a drug target is due to its involvement in various cellular processes, including cell adhesion, migration, and the regulation of gene expression. Further studies are needed to fully understand the function of LINC00486 and its potential as a drug target.

Protein Name: Long Intergenic Non-protein Coding RNA 486

The "LINC00486 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00486 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets